A study of nemolizumab for babies with eczema
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is between 6 and 23 months old at the start of the study.
- Your baby has moderate to severe eczema diagnosed by a doctor.
- Your baby has not had enough relief from standard eczema creams or needs stronger treatment.
- You agree to apply moisturizer daily and follow the study schedule.
- Your baby weighs at least 11 pounds (5 kg).
- Your baby has not used certain strong eczema treatments or vaccines in the weeks before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.
This study tests a new injected medication called nemolizumab for people with moderate-to-severe eczema (atopic dermatitis) that hasn't been controlled by creams or ointments. The goal is to see if it reduces symptoms like itching and skin inflammation better than a placebo (inactive shot).
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.